Company: SNSE
Filing Date: 2025-04-11
Form Type: DEF 14A
Source: 0000950170-25-053033
Chunk: 47

Company: Sensei Biotherapeutics, Inc.
Filing Date: 2025-04-11
Form: DEF 14A
Chunk 47
---
st was 55%, 40% and 40%, respectively, of their respective base salaries.

The actual performance-based annual bonus paid, if any, has historically been calculated by multiplying the executive’s annual base salary at year-end, target bonus percentage and, respectively, the percentage attainment of the corporate goals established for such year, and the percentage attainment of individual goals. However, the Compensation Committee is not required to calculate bonuses in this manner and retains discretion in the amounts it awards and the factors it takes into consideration in determining bonus amounts. After the end of the year, the Compensation Committee reviews our performance against our goals and approves the extent to which our executives achieved each of our corporate and individual goals, as applicable, and, for each named executive officer, the amount of the bonus awarded.

Our 2024 corporate goals consisted of research and development, business development and financial objectives. In early 2025, the Compensation Committee determined that the 2024 corporate goals were achieved at a 82.5% level. After considering the achievement of the 2024 corporate goals together with individual goals where applicable, the Compensation Committee awarded Mr. Celebi, Ms. Krebs and Dr. van der Horst 91.3%, 91.3% and 88.8% of their target bonuses, respectively, for the year ended December 31, 2024. The actual bonus amounts paid are reflected in the “Non-Equity Incentive Plan Compensation” column of the Summary Compensation Table above.

Equity-Based Incentive Awards

We believe that equity awards provide our executives with a strong link to our long-term performance, create an ownership culture and align the interests of our executives and our stockholders. We believe that our equity awards are an important retention tool for our executive officers, as well as for our other employees.

We award equity awards broadly to our employees. Grants to our executives and other employees are made at the discretion of our board of directors and Compensation Committee. Our Compensation Committee grants stock options, restricted stock units, or a combination of both to our employees, including our named executive officers.

On February 15, 2024, Mr. Celebi and Dr. van der Horst were granted stock options to purchase 315,000 shares and 125,000 shares, respectively. One-fourth of the shares underlying the stock options vest on February 15, 2025, with the remainder vesting monthly over an additional 36 months of continuous service.

On December 20, 2024